MDWD $1.28 --FDA Decision in 2 Weeks ..Cheap and well financed biotech with huge upside Market Cap $52 million / Cash Balance $34.5 million additional 7.5 million milestone payment expected upon FDA approval NexoBrid PDUFA date of January 1, 2023; Upon approval, NexoBrid expected to generate meaningful revenues Company focused on the billion-dollar market opportunity with EscharEx Phase 3 clinical study to begin in first-half 2023 $30.5 million in gross proceeds raised; operating cash runway through 2025 Presentation https://ir.mediwound.com/static-files/0ea1057e-b20d-4acf-914a-e5e344982438